Evidence map›Paper›PMID 31577842›Full record

Observational studyInternational journal of cancer2020

Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study.

Philip E Castle, Robert D Burk, Leslie S Massad, Isam-Eldin Eltoum, Charles B Hall, Nancy A Hessol, Kathryn Anastos, Xianhong Xie, Howard Minkoff, Xiaonan Xue and 7 more

Open access · greenAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Philip E CastleAlbert Einstein College of Medicine, Bronx, NY.ORCID 0000-0003-1082-6554
Robert D BurkAlbert Einstein College of Medicine, Bronx, NY.ORCID 0000-0002-8376-8458
Leslie S MassadWashington University School of Medicine, St. Louis, MO.ORCID 0000-0001-8486-9464
Isam-Eldin EltoumUniversity of Alabama, Birmingham, AB.
Charles B HallAlbert Einstein College of Medicine, Bronx, NY.
Nancy A HessolUniversity of California, San Francisco, CA.
Kathryn AnastosAlbert Einstein College of Medicine, Bronx, NY.
Xianhong XieAlbert Einstein College of Medicine, Bronx, NY.
Howard MinkoffMaimonides Medical Center, Brooklyn, NY.
Xiaonan XueAlbert Einstein College of Medicine, Bronx, NY.
Gypsyamber D'SouzaJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Lisa FlowersEmory University School of Medicine, Atlanta, GA.
Christine ColieGeorgetown University Medical Center, Washington, DC.
Lisa RahangdaleUniversity of North Carolina School of Medicine, Chapel Hill, NC.
Margaret A FischlUniversity of Miami Miller School of Medicine, Miami, FL.
Joel M PalefskyUniversity of California, San Francisco, CA.
Howard D StricklerAlbert Einstein College of Medicine, Bronx, NY.ORCID 0000-0002-7692-6147
Albert Einstein College of Medicine · USUniversity of California, San Francisco · USEmory University · USGeorgetown University · USJohns Hopkins University · USMaimonides Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Miami · USUniversity of North Carolina at Chapel Hill · USWashington University in St. Louis · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000454NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA085178NCI NIH HHS R01 CA174634NCI NIH HHS R01 CA230331NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146202NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01 AI103408NIAID NIH HHS UM1 AI035043NICHD NIH HHS U01 HD032632
6 · The paper itself

Abstract

Infection by human papillomavirus (HPV) type 16, the most oncogenic HPV type, was found to be the least affected by HIV-status and CD4 count of any of the approximately 13 oncogenic HPV types. This relative independence from host immune status has been interpreted as evidence that HPV16 may have an innate ability to avoid the effects of immunosurveillance. However, the impact of immune status on other individual HPV types has not been carefully assessed. We studied type-specific HPV infection in a cohort of 2,470 HIV-positive (HIV[+]) and 895 HIV-negative (HIV[-]) women. Semi-annually collected cervicovaginal lavages were tested for >40 HPV types. HPV type-specific prevalence ratios (PRs), incidence and clearance hazard ratios (HRs), were calculated by contrasting HPV types detected in HIV[+] women with CD4 < 200 to HIV[-] women. HPV71 and HPV16 prevalence had the weakest associations with HIV-status/CD4 count of any HPV, according to PRs. No correlations between PRs and HPV phylogeny or oncogenicity were observed. Instead, higher HPV type-specific prevalence in HIV[-] women correlated with lower PRs (ρ = -0.59; p = 0.0001). An alternative (quadratic model) statistical approach (P

Indexed as

Immune EvasionAdultCD4 Lymphocyte CountCervix UteriDNA, ViralFemaleHIV SeropositivityHumansPapanicolaou TestPapillomaviridaePapillomavirus InfectionsPhylogenyPrevalenceProspective StudiesUterine Cervical NeoplasmsYoung AdultDNA, Viral

Identifiers

PMID31577842
PMCPMC7373334
OpenAlexW2977261011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.